Table 3.
Changes in VGLUT1 immunoreactivity in female APOE3 and APOE4 mice
| 30 dpl |
70 dpl |
170 dpl |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sh.e3 | Les.e3 | p | Sh.e4 | Les.e4 | p | Sh.e3 | Les.e3 | p | Sh.e4 | Les.e4 | p | Sh.e3 | Les.e3 | p | Sh.e4 | Les.e4 | p | |
| DG oML | 1 ± 0.04 | 0.80 ± 0.04 | 0.01 | 1 ± 0.03 | 0.90 ± 0.03 | 0.18 | 1 ± 0.07 | 0.85 ± 0.03 | 0.07 | 1 ± 0.05 | 0.85 ± 0.08 | 0.07 | 1 ± 0.05 | 0.93 ± 0.06 | 0.40 | 1 ± 0.06 | 0.79 ± 0.05 | 0.01 |
| DG mML | 1 ± 0.03 | 0.73 ± 0.04 | 0.01 | 1 ± 0.04 | 0.68 ± 0.03 | 0.01 | 1 ± 0.05 | 0.87 ± 0.03 | 0.12 | 1 ± 0.05 | 0.82 ± 0.08 | 0.03 | 1 ± 0.06 | 0.93 ± 0.06 | 0.39 | 1 ± 0.05 | 0.82 ± 0.04 | 0.02 |
| DG iML | 1 ± 0.02 | 0.94 ± 0.06 | 0.45 | 1 ± 0.06 | 0.94 ± 0.03 | 0.45 | 1 ± 0.06 | 0.97 ± 0.05 | 0.77 | 1 ± 0.06 | 0.91 ± 0.10 | 0.29 | 1 ± 0.06 | 0.99 ± 0.06 | 0.92 | 1 ± 0.08 | 0.91 ± 0.04 | 0.24 |
| DG HIL | 1 ± 0.02 | 1.01 ± 0.03 | 0.82 | 1 ± 0.04 | 0.91 ± 0.03 | 0.26 | 1 ± 0.07 | 0.97 ± 0.04 | 0.74 | 1 ± 0.05 | 0.92 ± 0.08 | 0.34 | 1 ± 0.04 | 1.08 ± 0.03 | 0.24 | 1 ± 0.04 | 0.93 ± 0.02 | 0.39 |
| CA3 oLM | 1 ± 0.04 | 0.80 ± 0.04 | 0.01 | 1 ± 0.03 | 0.98 ± 0.03 | 0.88 | 1 ± 0.06 | 0.94 ± 0.02 | 0.48 | 1 ± 0.07 | 0.88 ± 0.09 | 0.13 | 1 ± 0.04 | 0.91 ± 0.05 | 0.89 | 1 ± 0.05 | 0.80 ± 0.04 | 0.01 |
| CA3 iLM | 1 ± 0.03 | 0.75 ± 0.04 | 0.01 | 1 ± 0.05 | 0.85 ± 0.03 | 0.04 | 1 ± 0.05 | 0.88 ± 0.03 | 0.12 | 1 ± 0.06 | 0.84 ± 0.08 | 0.04 | 1 ± 0.03 | 0.92 ± 0.04 | 0.60 | 1 ± 0.04 | 0.83 ± 0.05 | 0.02 |
| CA3 RAD | 1 ± 0.02 | 0.89 ± 0.04 | 0.14 | 1 ± 0.04 | 0.96 ± 0.03 | 0.59 | 1 ± 0.06 | 0.99 ± 0.03 | 0.92 | 1 ± 0.07 | 0.94 ± 0.09 | 0.51 | 1 ± 0.03 | 1.01 ± 0.04 | 0.35 | 1 ± 0.03 | 0.87 ± 0.04 | 0.09 |
| CA3 LUC | 1 ± 0.03 | 0.97 ± 0.05 | 0.68 | 1 ± 0.05 | 0.96 ± 0.03 | 0.61 | 1 ± 0.07 | 0.97 ± 0.03 | 0.76 | 1 ± 0.06 | 0.93 ± 0.08 | 0.43 | 1 ± 0.03 | 1.00 ± 0.05 | 0.10 | 1 ± 0.04 | 0.89 ± 0.03 | 0.15 |
| CA3 OR | 1 ± 0.03 | 0.95 ± 0.02 | 0.56 | 1 ± 0.05 | 0.90 ± 0.04 | 0.19 | 1 ± 0.05 | 0.93 ± 0.05 | 0.43 | 1 ± 0.04 | 0.85 ± 0.06 | 0.06 | 1 ± 0.04 | 1.03 ± 0.03 | 0.91 | 1 ± 0.06 | 0.92 ± 0.05 | 0.30 |
| CA2 oLM | 1 ± 0.04 | 0.81 ± 0.05 | 0.01 | 1 ± 0.03 | 1.02 ± 0.04 | 0.75 | 1 ± 0.05 | 0.92 ± 0.04 | 0.32 | 1 ± 0.06 | 0.85 ± 0.09 | 0.06 | 1 ± 0.05 | 0.93 ± 0.05 | 0.98 | 1 ± 0.04 | 0.81 ± 0.05 | 0.01 |
| CA2 iLM | 1 ± 0.03 | 0.76 ± 0.05 | 0.01 | 1 ± 0.06 | 0.81 ± 0.04 | 0.01 | 1 ± 0.05 | 0.88 ± 0.03 | 0.15 | 1 ± 0.05 | 0.83 ± 0.08 | 0.03 | 1 ± 0.05 | 0.88 ± 0.05 | 0.27 | 1 ± 0.04 | 0.74 ± 0.03 | 0.01 |
| CA2 RAD | 1 ± 0.02 | 0.93 ± 0.06 | 0.39 | 1 ± 0.04 | 0.97 ± 0.06 | 0.76 | 1 ± 0.06 | 1.02 ± 0.03 | 0.76 | 1 ± 0.07 | 0.93 ± 0.08 | 0.38 | 1 ± 0.03 | 1.01 ± 0.04 | 0.34 | 1 ± 0.03 | 0.88 ± 0.04 | 0.11 |
| CA2 OR | 1 ± 0.03 | 0.95 ± 0.03 | 0.57 | 1 ± 0.07 | 0.95 ± 0.02 | 0.55 | 1 ± 0.05 | 0.99 ± 0.04 | 0.92 | 1 ± 0.08 | 0.92 ± 0.09 | 0.33 | 1 ± 0.03 | 0.99 ± 0.03 | 0.92 | 1 ± 0.03 | 1.03 ± 0.05 | 0.64 |
| CA1 LM | 1 ± 0.03 | 0.99 ± 0.06 | 0.93 | 1 ± 0.07 | 0.88 ± 0.03 | 0.24 | 1 ± 0.04 | 1.03 ± 0.06 | 0.76 | 1 ± 0.07 | 0.91 ± 0.06 | 0.41 | 1 ± 0.03 | 1.09 ± 0.03 | 0.37 | 1 ± 0.06 | 1.02 ± 0.06 | 0.79 |
| CA1 RAD | 1 ± 0.02 | 0.98 ± 0.07 | 0.85 | 1 ± 0.08 | 0.78 ± 0.08 | 0.02 | 1 ± 0.07 | 1.06 ± 0.05 | 0.53 | 1 ± 0.13 | 0.92 ± 0.13 | 0.48 | 1 ± 0.02 | 1.16 ± 0.07 | 0.15 | 1 ± 0.16 | 0.83 ± 0.03 | 0.09 |
| CA1 OR | 1 ± 0.02 | 0.87 ± 0.05 | 0.20 | 1 ± 0.05 | 0.82 ± 0.05 | 0.06 | 1 ± 0.06 | 0.91 ± 0.03 | 0.39 | 1 ± 0.04 | 0.87 ± 0.08 | 0.23 | 1 ± 0.04 | 1.01 ± 0.07 | 0.94 | 1 ± 0.09 | 0.82 ± 0.05 | 0.07 |
VGLUT1 immunoreactivity levels are provided for all female groups (expressed as a ratio of respective sham group). Significant differences (p < 0.05, Fisher's LSD) are highlighted in red. Data are presented as mean ± SEM.